Allarity Therapeutics, Inc. (ALLR)
(Delayed Data from NSDQ)
$1.54 USD
-0.04 (-2.53%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.53 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLR 1.54 -0.04(-2.53%)
Will ALLR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALLR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLR
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
ALLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLR
ALLR Fell Below 20 Day Moving Average on September 19
ALLR Crossed Above 20 Day Moving Average on September 18
Is ALLR building bullish momentum? 1,2,3 Pullback Bullish shows up after declining 3.29%
ALLR forms 20 Day Moving Average Support on September 16
Technical picture remains unchanged for ALLR after it falls 1.81% on September 15